HRP20100363T1 - Nove kombinacije antagonista receptora 5-ht3 s racekatodrilom ili deksekatodrilom - Google Patents

Nove kombinacije antagonista receptora 5-ht3 s racekatodrilom ili deksekatodrilom Download PDF

Info

Publication number
HRP20100363T1
HRP20100363T1 HR20100363T HRP20100363T HRP20100363T1 HR P20100363 T1 HRP20100363 T1 HR P20100363T1 HR 20100363 T HR20100363 T HR 20100363T HR P20100363 T HRP20100363 T HR P20100363T HR P20100363 T1 HRP20100363 T1 HR P20100363T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical preparation
combination
diarrhea
treatment
combination according
Prior art date
Application number
HR20100363T
Other languages
English (en)
Croatian (hr)
Inventor
Schwartz Jean-Charles
Lecomte Jeanne-Marie
Original Assignee
Bioprojet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34684783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100363(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioprojet filed Critical Bioprojet
Publication of HRP20100363T1 publication Critical patent/HRP20100363T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
HR20100363T 2004-02-12 2010-06-29 Nove kombinacije antagonista receptora 5-ht3 s racekatodrilom ili deksekatodrilom HRP20100363T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04290384A EP1563848A1 (de) 2004-02-12 2004-02-12 Neue Kombinationen von Antiemetika und Enkephalinase-Inhibitoren
PCT/IB2005/000351 WO2005079850A1 (en) 2004-02-12 2005-02-14 New combinations of an anti emetic agent and an enkephalinase inhibitor

Publications (1)

Publication Number Publication Date
HRP20100363T1 true HRP20100363T1 (hr) 2010-07-31

Family

ID=34684783

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100363T HRP20100363T1 (hr) 2004-02-12 2010-06-29 Nove kombinacije antagonista receptora 5-ht3 s racekatodrilom ili deksekatodrilom

Country Status (28)

Country Link
US (1) US8222294B2 (de)
EP (2) EP1563848A1 (de)
JP (1) JP4987487B2 (de)
KR (1) KR101152308B1 (de)
CN (1) CN1917903B (de)
AT (1) ATE468138T1 (de)
AU (1) AU2005215262B2 (de)
BR (1) BRPI0506631B8 (de)
CA (1) CA2553827C (de)
CY (1) CY1110202T1 (de)
DE (1) DE602005021317D1 (de)
DK (1) DK1718337T3 (de)
EA (1) EA010625B1 (de)
EC (1) ECSP066758A (de)
ES (1) ES2344909T3 (de)
HR (1) HRP20100363T1 (de)
MA (1) MA28354A1 (de)
ME (1) ME01175B (de)
NO (1) NO337320B1 (de)
NZ (1) NZ548635A (de)
PL (1) PL1718337T3 (de)
PT (1) PT1718337E (de)
RS (1) RS51329B (de)
SI (1) SI1718337T1 (de)
TN (1) TNSN06246A1 (de)
UA (1) UA88156C2 (de)
WO (1) WO2005079850A1 (de)
ZA (1) ZA200605872B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2900823B1 (fr) * 2006-05-15 2009-02-13 Bioprojet Soc Civ Ile Nouvelle forme d'administration du racecadotril.
EP2462922A1 (de) * 2010-12-10 2012-06-13 Bioprojet Neue Darreichungsform für Enkephalinasehemmer
US9114171B2 (en) * 2012-06-28 2015-08-25 Mcneil-Ppc, Inc. Racecadotril liquid compositions
KR20150023876A (ko) 2012-06-28 2015-03-05 맥네일-피피씨, 인코포레이티드 라세카도트릴 지질 조성물
JP6282644B2 (ja) * 2012-06-28 2018-02-21 ジヨンソン・アンド・ジヨンソン・コンシユーマー・インコーポレーテツドJohnson & Johnson Consumer Inc. ラセカドトリル液体組成物
US9801819B2 (en) * 2012-06-28 2017-10-31 Johnson & Johnson Consumer Inc. Racecadotril compositions
MA40859A (fr) 2014-10-29 2017-09-05 Johnson & Johnson Consumer Inc Particules de cadotril

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins

Also Published As

Publication number Publication date
PT1718337E (pt) 2010-06-16
ME01175B (me) 2013-03-20
NO20063973L (no) 2006-09-05
EP1718337B1 (de) 2010-05-19
DE602005021317D1 (de) 2010-07-01
EA010625B1 (ru) 2008-10-30
ECSP066758A (es) 2006-11-24
EP1563848A1 (de) 2005-08-17
AU2005215262B2 (en) 2011-03-03
CA2553827A1 (en) 2005-09-01
EA200601466A1 (ru) 2006-12-29
BRPI0506631A (pt) 2007-05-08
CY1110202T1 (el) 2015-01-14
BRPI0506631B8 (pt) 2021-05-25
WO2005079850A1 (en) 2005-09-01
DK1718337T3 (da) 2010-07-26
CN1917903A (zh) 2007-02-21
KR101152308B1 (ko) 2012-06-11
EP1718337A1 (de) 2006-11-08
CA2553827C (en) 2012-08-07
NZ548635A (en) 2009-10-30
JP4987487B2 (ja) 2012-07-25
MA28354A1 (fr) 2006-12-01
BRPI0506631B1 (pt) 2018-12-04
UA88156C2 (ru) 2009-09-25
US20070275993A1 (en) 2007-11-29
ZA200605872B (en) 2008-01-08
JP2007522202A (ja) 2007-08-09
ATE468138T1 (de) 2010-06-15
AU2005215262A1 (en) 2005-09-01
NO337320B1 (no) 2016-03-07
RS51329B (en) 2011-02-28
KR20060132691A (ko) 2006-12-21
SI1718337T1 (sl) 2010-08-31
TNSN06246A1 (fr) 2007-12-03
PL1718337T3 (pl) 2010-09-30
US8222294B2 (en) 2012-07-17
CN1917903B (zh) 2010-07-21
ES2344909T3 (es) 2010-09-09

Similar Documents

Publication Publication Date Title
HRP20100363T1 (hr) Nove kombinacije antagonista receptora 5-ht3 s racekatodrilom ili deksekatodrilom
BRPI0309142C1 (pt) suspensão de microcápsulas em uma fase líquida aquosa, que permite a liberação modificada de pelo menos um princípio ativo com exclusão da amoxicilina e que é destinada a ser administrada por via oral
AR045076A1 (es) Composicion de pelicula que se disuelve oralmente, pelicula multicomponente que se disuelve oralmente, uso de la composicion de pelicula y de la pelicula que se disuelve oralmente para preparar un medicamento, forma de dosificacion oral y procedimiento para preparar la composicion de pelicula que se
CY1115652T1 (el) Μορφη δοσολογιας που περιεχει δυο δραστικα φαρμακευτικα συστατικα μειγματος σε διαφορετικες φυσικες μορφες
BR0206627A (pt) Formulação farmacêutica
HRP20240082T1 (hr) Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti
AR059324A2 (es) Una forma solida de dosificacion oral
MX2010008234A (es) Nueva dosificacion y formulacion.
MX2007006212A (es) Medicamento oral para liberacion modificada de al menos un principio activo bajo forma multimicrocapsular.
JP2009525343A5 (de)
SV2002000250A (es) Formula de dosis de droga accionada por hidrogel ref. pc10818ajtb/bb
PE20050728A1 (es) Forma de dosificacion a prueba de abuso
MY177027A (en) Novel dosage and formulation
HRP20140759T1 (hr) Kompozicije za lijeäśenje središnje posredovane muäśnine i povraä†anja
SI2729130T1 (en) Combined formulations of darunavir
RU2010147287A (ru) Комбинированная композиция
AR098745A2 (es) Composición, kit y uso de compuestos quimioterapéuticos
SI2889033T1 (en) Treatment of negative symptoms of schizophrenia with (R) -7-chloro-N- (chonylidin-3-yl) benzo (B) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
AP2003002763A0 (en) Controlled release formulations for oral administration
HRP20161340T1 (hr) Formulacije darunavira
JP2007522202A5 (de)
AR012480A1 (es) Una unidad de dosis farmaceutica que comprende tibolona, un metodo para elaborarla y el uso de un producto de almidon como vehiculo en unidades dedosis farmaceuticas que comprenden tibolona
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
TR200101928T2 (tr) Geliştirilmiş kararlılığa sahip bileşimler
BRPI0715756B8 (pt) composição farmacêutica para administração oral, seus usos, e medicamento